| Value | ₹150.0 Cr |
|---|---|
| Execution period | 18 months |
BSE filing, NSE: KRITI. Summary written from the filing by ALFA Finder's alert engine.
Kriti Industries (India) Ltd: key numbers
- Share price
- ₹48.03
- Market cap
- ₹253.1 Cr
- Revenue (annual)
- ₹587.4 Cr
- Net profit (annual)
- ₹1.13 Cr
- P/E (TTM)
- -30.4×Sector 51.5×
- Promoter holding
- 69.07%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kriti Industries (India) Ltd
All →Kriti Industries (India) Board Meeting Date
Kriti Industries schedules a board meeting on 5 November 2026 to approve Q2 and half-year unaudited financial results. The filing is an advance intimation of a future board meeting.
Kriti Industries (India) Other Announcement
This is a periodic Shareholding Pattern filing pursuant to SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Kriti Industries (India) Management Change
CS Aditi Randhar has resigned from her position as Company Secretary, Compliance Officer, and Key Managerial Personnel of Kriti Industries (India) Limited, effective September 21, 2026.
Kriti Industries (India) Annual General Meeting
Kriti Industries (India) filed the minutes of its 36th AGM held August 12, 2026. The meeting ran via OAVM and closed at 3:47 P.M.
Kriti Industries (India) Annual General Meeting
Kriti Industries (India) Limited held its 36th Annual General Meeting on August 12, 2026, via video conferencing. The meeting covered standard business resolutions including adoption of financial statements.
Kriti Industries (India) Employee Stock Options
Kriti Industries (India) Limited granted 1,00,000 ESOPs to eligible employees at an exercise price of Rs. 67.62. The grant follows the company's 2024 Stock Option Plan.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr